Figure 6.
Figure 6. Addition of recombinant TRAIL to ApoE−/−/TRAIL−/− mice reestablished the development of PAH. (A–D) Bar graphs show RVSP (A), RVEDP (B), LVESP (C), and LVEDP (D), measured in mm Hg. (E–H) PA AT (E), cardiac index (F), ePVRi (G), and RVH (H). (I) The degree of medial wall thickness as a ratio of total vessel size (Media/CSA) in pulmonary arteries <50 µm in diameter. (J) Representative photomicrographs of serial lung sections from ApoE−/−/TRAIL−/− mice fed Paigen diet for 8 wk who received either recombinant TRAIL (rTRAIL) or saline (placebo) by osmotic micro-pump for 4 wk. Sections were stained with Alcian Blue Elastic van Gieson (ABEVG) or immunostained for α-SMA. Error bars represent mean ± SEM, n = 4–5 animals per group. *, P < 0.05; **, P < 0.01 compared with placebo-treated mice. Bars, 50 µm.

Addition of recombinant TRAIL to ApoE−/−/TRAIL−/− mice reestablished the development of PAH. (A–D) Bar graphs show RVSP (A), RVEDP (B), LVESP (C), and LVEDP (D), measured in mm Hg. (E–H) PA AT (E), cardiac index (F), ePVRi (G), and RVH (H). (I) The degree of medial wall thickness as a ratio of total vessel size (Media/CSA) in pulmonary arteries <50 µm in diameter. (J) Representative photomicrographs of serial lung sections from ApoE−/−/TRAIL−/− mice fed Paigen diet for 8 wk who received either recombinant TRAIL (rTRAIL) or saline (placebo) by osmotic micro-pump for 4 wk. Sections were stained with Alcian Blue Elastic van Gieson (ABEVG) or immunostained for α-SMA. Error bars represent mean ± SEM, n = 4–5 animals per group. *, P < 0.05; **, P < 0.01 compared with placebo-treated mice. Bars, 50 µm.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal